Spectrum.Life, a leading provider of mental health and wellbeing services for insurers, employers, employees, and students is pleased to announce the successful completion of a €5 million raise, resulting in a total of €9…
Continue Reading
Today I’m speaking with Laura Simmons, CEO & Founder of Theratrak and Leanne Healey, Director Everyday Independance.In this part of 1 of 2, I’ve extracted from a live stream discussion I hosted late last…
Continue Reading
Safety is paramount in medical care, rooted in the most basic tenet of medicine: First, do no harm. But, although acute medical care presents myriad risks to patient safety, there is no category for…
Continue Reading
Each person is unique in how they react to prescription and over-the-counter medications. Factors like genetics and other medications you take can affect how you metabolize and respond to certain drugs. Understanding these factors…
Continue Reading
AbbVie turned to Capsida Biotherapeutics two years ago for help delivering gene therapies into the brain. That partnership is ongoing, but the pharmaceutical giant now wants to leverage its partner’s technology for delivery of…
Continue Reading
Teletherapy company Talkspace reported a total of $30.2 million in revenue for Q4 with its total earnings for 2022 at around $120 million, driven by growth in the business-to-business revenue. But the New York-based company…
Continue Reading
What You Should Know:– BrightInsight announced that ixlayer has joined the BrightInsight Ecosystem, a network of more than 20 of the world’s leading healthcare and technology companies driving growth and adoption of digital health solutions.– The BrightInsight Ecosystem of…
Continue Reading
Travere Therapeutics has won FDA approval for a drug that treats a rare autoimmune disorder that is typically first noticed as blood in the urine and can progress over time to end-stage kidney failure.
The…
Geographic atrophy, an eye disorder that starts as a loss of central vision and progressively worsens to total blindness, now has its first treatment. The FDA on Friday approved an Apellis Pharmaceuticals drug that slows the progression of this disease, which affects more than 1 million people in the U.S.
Approval of the Apellis drug, pegcetacoplan, covers all patients with geographic atrophy, a broad label that reflects the representative patient population tested in pivotal studies, Chief Medical Officer Caroline Baumal said during a Friday evening conference call. The Waltham, Massachusetts-based company plans to launch the drug in March, marketing the product under…
Researchers at the Harvard Wyss Institute and the Dana-Farber Cancer Institute have developed a new method to prepare chimeric antigen receptor-T cells (CAR-T cells) for leukemia patients that could result in more effective treatment. CAR-T cells start life as T cells that are isolated from cancer patients, are stimulated and primed to recognize and attack cancer cells, expanded in number, and then reintroduced to the cancer patient with the goal that the cells will destroy their cancer. However, the technique works better in certain patients, and the researchers behind this latest technique have realized that T-cells from cancer patients do […]…
Continue Reading
